Invitris

Executive Summary

Invitris is a German biotech company pioneering a cell-free protein synthesis platform that enables rapid design, expression, and scalable production of complex proteins. By combining proprietary Phactory™ reagents with high-throughput microfluidics, its technology accelerates protein engineering for drug discovery, antimicrobial development, and industrial biotechnology. Founded in 2020 and based in Munich, Invitris has raised €5 million to date, positioning itself as a platform player in the synthetic biology space. The platform's key advantages are speed and flexibility: it bypasses the need for living cells, reducing development timelines from months to weeks and enabling the production of difficult-to-express proteins. This is particularly valuable for oncology and infectious disease applications, where rapid protein prototyping can accelerate therapeutic candidate screening. With a team of 50–200 employees, Invitris is well-positioned to scale its technology and capture value across multiple end markets. However, the company remains at an early revenue stage, and its long-term success hinges on securing commercial partnerships and validating its platform in real-world drug development pipelines.

Upcoming Catalysts (preview)

• Q3 2026Series A funding round closure60% success
• Q4 2026Strategic partnership with a major pharmaceutical company50% success
• Q3 2026Launch of commercial Phactory™ reagent kit for research use70% success